Several barriers exist to high-efficiency transfer of therapeutic genes into human
hematopoietic stem cells (HSCs) using complex oncoretroviral vectors. Human clinical trials …

Replication-competent retrovirus (RCR) is a safety concern for individuals treated with
retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured …

We have developed a viral RNA (vRNA) dot blot assay for rapid identification of high-titer
retrovirus vector production by packaging cell clones. The procedure employs Trizol LS …

The majority of clinical trials for gene therapy currently employ retroviral-mediated gene
delivery. This is because the life cycle of the retrovirus is well understood and can be …

The successful genetic engineering of patient T cells with γ-retroviral vectors expressing
chimeric antigen receptors or T-cell receptors for phase II clinical trials and beyond requires …

Efforts to improve gene transfer (transduction) efficiency achieved with retroviral vectors
often focus on increasing the end-point titer. In this study, we assayed more than 70 …

Background Recently, several cancer gene therapy studies have shown that replication‐
competent retroviral vectors represent a major improvement over replication‐defective ones …

Background The ability to obtain high‐titer and large quantities of retroviral vector production
in a 'closed'system would have profound implications in clinical and experimental gene …

The improvement of safety and titer of retroviral vectors produced in standard retroviral
packaging cell lines is hampered because production relies on uncontrollable vector …

Most of the time, retrovirus vectors retain only cis-acting sequences from the original viral
genome. These sequences allow the recombinant structure to be transcribed (LTR …